Program Type: Midwest CEPAC

Interventions of Interest For questions please contact [email protected].

Interventions of Interest For questions please contact [email protected]. Final Documents

Intervention of Interest For questions please contact [email protected]. View the Key Stakeholder List. Final Documents

Interventions of Interest For questions please contact [email protected]. View the Key Stakeholder List. Final Documents

Interventions of Interest The independent appraisal committee vote was split on the net health benefit of suzetrigine compared to non-systemic therapies; suzetrigine has potential to be cost-saving due to avoided future cases of opioid use disorder. Final Documents For questions please contact [email protected]. View the Key Stakeholder List. ICER’s Chief Medical Officer David Rind, MD, […]

Interventions of Interest The independent appraisal committee voted that current evidence is adequate to demonstrate superior net health benefits for tafamidis, acoramidis, and vutrisiran when compared to no disease-specific therapy. Tafamidis and acoramidis would achieve common thresholds for cost-effectiveness if priced between $13,600 to $39,000 per year. Final Documents For questions please contact [email protected]. View […]

Interventions of Interest An independent appraisal committee voted that current evidence is adequate to demonstrate superior net health benefits for ensifentrine added to maintenance therapy compared to maintenance therapy alone. ICER calculated a health-benefit price benchmark (HBPB) for ensifentrine between $7,500 to $12,700 per year, and the therapy is priced at $35,400 per year  Final […]